NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023
Kelvin A. Moses, Preston C. Sprenkle, Clinton D. Bahler, Geoffrey N. Box, Sigrid Carlsson, William J. Catàlona, Douglas M. Dahl, Marc Dall’Era, John W. Davis, Bettina F. Drake, Jonathan I. Epstein, Ruth B. Etzioni, Thomas A. Farrington, Isla P. Garraway, David F. Jarrard, Eric Kauffman, Deborah R. Kaye, Adam S. Kibel, Chad A. LaGrange, Paul Maroni, Lee Ponsky, Brian Reys, Simpa S. Salami, Alejandro Sánchez, Tyler M. Seibert, Terrence Shaneyfelt, Marc C. Smaldone, Geoffrey A. Sonn, Mark D. Tyson, Neha Vapiwala, Robert Wake, Samuel L. Washington, Alice Yu, Bertram Yuh, Ryan A. Berardi, Deborah A. Freedman-Cass
Abstract
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.